Divesiran Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Divesiran Growth

• First-in-class siRNA therapy targeting TMPRSS6 with a differentiated mechanism:

Divesiran is an investigational small interfering RNA (siRNA) therapy that silences TMPRSS6, increasing endogenous hepcidin levels and restricting iron availability for erythropoiesis. This approach directly reduces excessive red blood cell production in PV and differs fundamentally from currently available cytoreductive agents or interferons. Its novel mechanism positions divesiran as a potentially disease-modifying therapy for patients who remain dependent on therapeutic phlebotomy.

• Promising Phase I efficacy with durable reduction in phlebotomy burden:

Data from the Phase I SANRECO study demonstrated durable hematocrit control (< 45%) and a substantial reduction in therapeutic phlebotomy requirements in phlebotomy-dependent PV patients. Follow-up analyses presented at the 2026 European Hematology Association (EHA) meeting showed that during the 16-week period after the final dose, only four phlebotomies were required, while among 14 patients with extended follow-up, the median time to first phlebotomy was 287 days. Improvements in PV-related symptom scores and quality of life were also reported, supporting long-lasting clinical benefit.

• Convenient infrequent dosing could improve long-term adherence:

The ongoing Phase II SANRECO trial is evaluating every-6-week (Q6W) and every-12-week (Q12W) subcutaneous dosing regimens. The prolonged pharmacodynamic activity observed in Phase I supports the feasibility of infrequent dosing, which could offer a significant advantage over therapies requiring more frequent administration or repeated phlebotomies, thereby improving patient convenience and treatment adherence.

• Rapid clinical development with important near-term catalysts:

Silence Therapeutics completed enrollment in the randomized Phase II SANRECO trial ahead of schedule, reflecting strong investigator and patient interest. The study enrolled 48 phlebotomy-dependent PV patients, with the primary endpoint evaluating maintenance of hematocrit below 45% without phlebotomy between Weeks 18 and 36. The company expects topline Phase II results in August 2026, making this one of the most significant near-term value inflection points for the program.

Divesiran Recent Developments

In October 2025, Silence Therapeutics announced it had completed patient enrollment in the SANRECO Phase II study of Divesiran, a first-in-class siRNA targeting TMPRSS6, for the treatment of polycythemia vera (PV). Initial topline results from the SANRECO Phase II study are anticipated in the third quarter of 2026.

“Divesiran Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Divesiran for potential indication like Polycythaemia vera in the 7MM. A detailed picture of Divesiran’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Divesiran for potential indications. The Divesiran market report provides insights about Divesiran’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Divesiran performance, future market assessments inclusive of the Divesiran market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Divesiran sales forecasts, along with factors driving its market.

Divesiran Drug Summary

Divesiran is an investigational, first-in-class small interfering RNA (siRNA) therapeutic developed by Silence Therapeutics for the treatment of polycythemia vera (PV). Administered as a subcutaneous injection, divesiran is designed to silence the TMPRSS6 gene in the liver, thereby increasing endogenous hepcidin production, the body's key regulator of iron metabolism. Elevated hepcidin restricts iron availability to the bone marrow, reducing the excessive iron-dependent production of red blood cells that characterizes polycythemia vera and helping maintain hematocrit control while reducing the need for therapeutic phlebotomy. The therapy has demonstrated promising pharmacodynamic activity and favorable safety in early clinical studies, with durable reductions in phlebotomy requirements and improvements in disease-related symptoms, and is currently being evaluated in Phase II clinical trials for PV. Divesiran has also received both FDA Fast Track and Orphan Drug designations for polycythemia vera, highlighting its potential as a novel disease-modifying treatment for this rare hematologic malignancy. The report provides Divesiran’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Divesiran Market Report

The report provides insights into:

• A comprehensive product overview including the Divesiran MoA, description, dosage and administration, research and development activities in potential indication like Polycythaemia vera.
• Elaborated details on Divesiran regulatory milestones and other development activities have been provided in Divesiran market report.
• The report also highlights Divesiran‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Divesiran market report also covers the patents information, generic entry and impact on cost cut.
• The Divesiran market report contains current and forecasted Divesiran sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Divesiran market report also features the SWOT analysis with analyst views for Divesiran in potential indications.

Methodology

The Divesiran market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Divesiran Analytical Perspective

• In-depth Divesiran Market Assessment

This Divesiran sales market forecast report provides a detailed market assessment of Divesiran for potential indication like Polycythaemia vera in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Divesiran sales data uptil 2034.

• Divesiran Clinical Assessment

The Divesiran market report provides the clinical trials information of Divesiran for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Divesiran Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Divesiran Market Potential & Revenue Forecast

• Projected market size for the Divesiran and its key indications
• Estimated Divesiran sales potential (Divesiran peak sales forecasts)
• Divesiran Pricing strategies and reimbursement landscape

Divesiran Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Divesiran Market positioning compared to existing treatments
• Divesiran Strengths & weaknesses relative to competitors

Divesiran Regulatory & Commercial Milestones

• Divesiran Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Divesiran Clinical Differentiation

• Divesiran Efficacy & safety advantages over existing drugs
• Divesiran Unique selling points

Divesiran Market Report Highlights

• In the coming years, the Divesiran market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Divesiran companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Divesiran’s dominance.
• Other emerging products for Polycythaemia vera are expected to give tough market competition to Divesiran and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Divesiran in potential indications.
• Analyse Divesiran cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Divesiran sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Divesiran in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Divesiran? How strong is Divesiran’s clinical and commercial performance?
• What is Divesiran’s clinical trial status in each individual indications such as Polycythaemia vera and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Divesiran Manufacturers?
• What are the key designations that have been granted to Divesiran for potential indications? How are they going to impact Divesiran’s penetration in various geographies?
• What is the current and forecasted Divesiran market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Divesiran in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Divesiran for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Divesiran? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.